Hip Osteoarthritis and Mesenchymal stem/stromal cells (MSC): what the trial registry contains
The ClinicalTrials.gov registry holds 7 records for MSC in Hip Osteoarthritis: 0 recruiting now, 0 labelled Phase 3 or 4, across 4 countries. Snapshot 2026-08-29.
Why this is studied in Hip Osteoarthritis
Hip osteoarthritis involves cartilage loss in a deep, high-load joint with limited access for injection and less intra-articular volume than the knee. Registered cell work is markedly thinner here than for knees, which is a useful cross-check when a clinic quotes knee data to justify a hip procedure.
What MSC means in this table
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
The numbers
Every figure below comes from one reproducible query (hip osteoarthritis x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 7 |
| Interventional studies in the sample | 7 |
| Recruiting right now | 0 |
| Completed | 1 |
| Terminated, withdrawn or suspended | 1 |
| Phase 3 or Phase 4 records | 0 |
| Countries with at least one site | 4 |
| Median planned enrolment | 100 participants |
| Largest single planned enrolment | 300 participants |
| First / most recent start year | 2010 — 2023 |
How mature is this evidence?
Read this as a research question rather than a treatment option: 7 early-stage records, 0 recruiting.
1 records are marked completed and 1 ended early (terminated, withdrawn or suspended): 14% of registrations did not run to plan.
| Phase label | Records | Share |
|---|---|---|
| Phase 1 | 5 | 56% |
| Phase 2 | 3 | 33% |
| Not applicable | 1 | 11% |
Median planned enrolment is 100 participants (largest single study: 300). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Across 4 countries with registered sites, United States dominates at roughly 33% — a concentration driven by funding and regulation rather than by clinical outcome.
| Country | Studies with a site there |
|---|---|
| United States | 2 |
| Poland | 2 |
| Canada | 1 |
| Iran | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Sponsorship leans commercial: 3 of the most frequent lead sponsors read as academic or hospital entities and 4 as companies. Who pays shapes what gets measured and what gets published.
- Medical University of Warsaw — 2 records
- Mayo Clinic — 1 record
- Nova Scotia Health Authority — 1 record
- Stem Cells Arabia — 1 record
- Royan Institute — 1 record
- Celltex Therapeutics Corporation — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT03608579 — Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA | Phase 1 | Active Not Recruiting | 24 | Mayo Clinic | 2018-11-05 |
| NCT04448106 — Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis | Phase 2 | Unknown | 300 | Celltex Therapeutics Corporation | 2023-09-25 |
| NCT03869229 — Adipose-derived Mesenchymal Stem Cells in Osteoarthritis | Phase 1, Phase 2 | Unknown | 100 | Medical University of Warsaw | 2019-04-05 |
| NCT03866330 — Wharton's Jelly-derived Mesenchymal Stem Cells in Osteoarthritis | Phase 1, Phase 2 | Unknown | 100 | Medical University of Warsaw | 2019-03-01 |
| NCT03067870 — Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis | Phase 1 | Unknown | 100 | Stem Cells Arabia | 2016-11 |
| NCT01499056 — Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint | Phase 1 | Completed | 6 | Royan Institute | 2010-06 |
| NCT03410355 — Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis | n/a | Terminated | 6 | Nova Scotia Health Authority | 2018-02-01 |
What this page does and does not tell you
Treat this as a map of research activity. It tells you whether a claim has an evidence programme behind it — not whether the treatment helped anyone.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many MSC studies for Hip Osteoarthritis are recruiting right now?
0 of 7 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is MSC an approved treatment for Hip Osteoarthritis?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 7 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on MSC for Hip Osteoarthritis?
0 of 7 records carry a Phase 3 or Phase 4 label and 1 are marked completed. Registrations run from 2010 to 2023.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.